Skip to content
Riskpilot
← Back to search
Sign in
Get full access
ALGIPHARMA AS
AS
Active
Org 964911444
Industriveien 33, 1337
Sandvika
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 1992 · 34 years old
6 employees
Monitor
Share
Norway
/
Companies
/
Research and experimental development on natural sciences and engineering
/
ALGIPHARMA AS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
NOK millions
0M
0M
1M
1M
1M
0M
2020
0M
2021
0M
2022
0M
2023
0M
2024
EBITDA
NOK millions
0M
-3M
-6M
-8M
-11M
-9M
2020
-7M
+22%
2021
-8M
-14%
2022
-6M
+25%
2023
-7M
-17%
2024
Income statement
NOK thousands
Item
2020
2021
2022
2023
2024
Revenue
0
65
40
86
6
Staff expenses
−2 705
−2 561
−2 237
−7 743
−8 649
EBITDA
−8 758
−6 509
−7 945
−5 821
−6 823
Depreciation & amort.
−143
−128
−0
−23
−35
EBIT
−8 902
−6 637
−7 945
−5 844
−6 858
Net financials
−3 404
−4 021
872
−3 988
−2 104
Profit before tax
−12 306
−10 658
−7 073
−9 832
−8 963
Tax
−0
−0
−0
−116
−0
Net profit
−12 306
−10 658
−7 073
−9 716
−8 963
Balance sheet
NOK thousands
Item
2020
2021
2022
2023
2024
Total assets
144 458
155 526
173 351
188 879
207 326
Equity
45 619
34 962
27 888
128 588
176 145
Long-term debt
89 336
112 260
127 767
47 666
14 824
Short-term debt
9 503
8 305
17 695
12 625
16 356
Total debt
98 839
120 565
145 463
60 291
31 180
Financial ratios
5-year trend
EBITDA margin
-118911.4%
This company
15.8%
Market median
-752704% vs market
2020
2024
Equity ratio
85.0%
This company
38.2%
Market median
+123% vs market
2020
2024
Return on equity
-5.1%
This company
18.4%
Market median
-128% vs market
2020
2024
Net profit margin
-156195.6%
This company
8.1%
Market median
-1928441% vs market
2020
2024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2020
2024
Debt / equity
0.18×
This company
0.62×
Market median
+71% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
View
PDF
More on ALGIPHARMA AS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
